BXCL501

Asset

Selective alpha-2 adrenergic receptor agonist

Stage: Phase 3
Modality: Small molecule
Target: ADRA2A; 2
Indications: 1
Trial: 1
Developer

Indications

2

Agitation
Phase 3, Terminated, NCT05665088, clinicaltrials.gov, 7 Oct 2026
Dementia
Phase 3, Terminated, NCT05665088, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Trials1
Competitors4

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 1 source